MYO-101 Phase 1/2a systemic gene therapy trial for LGMD2E to begin in early 2018 New Albany, OH, 13 December 2017 – Myonexus Therapeutics, Inc. (Myonexus), a clinical-stage biotechnology company developing… Read more
Myonexus Therapeutics is a clinical stage gene therapy company developing first-ever gene treatments for multiple types of limb-girdle muscular dystrophy (LGMD), a group of progressive, debilitating musculoskeletal genetic diseases that… Read more
Learn what investors already know: Early market validating is critical for pre-concept stage companies.
There’s good news in healthcare for investors and entrepreneurs. PitchBook reports that in 2015, VCs have invested nearly $21 billion in capital. That’s $2 billion more than in all of… Read more
Every startup has a vision statement. But Ohio State spinout Sight4All takes the idea of a vision statement to exciting new heights with a “vision,” not just for the company,… Read more
At 45 deals, Rev1 leads the pack of top VC investors in the US Great Lakes region since 2012, reported by venture capital research firm PitchBook. Three other Ohio VCs… Read more
Secret App is closing it’s doors. $10MM+ Series A rounds. $100MM valuations. $25MM+ for Series B. $500MM+ valuations. Some weeks it’s easy to wonder what’s going on. And then there’s… Read more
Results exceeded expectations for the inaugural session of Rev1 Ventures’ new Concept Academy. The Academy is designed specifically to help companies figure out: a direction for their business, initial market… Read more